Why It Matters
Kansas House Speaker Dan Hawkins is blocking legislative action on a Senate-passed drug pricing bill that hospitals, clinics, and a bipartisan coalition of lawmakers say is critical to protecting a federal program that discounts prescription costs and generates revenue for patient care. Senate Bill 284, the Defense of Drug Delivery Act, passed the Kansas Senate with overwhelming bipartisan support in March 2025 but has stalled in the House for over a year. The bill addresses how private companies extract sensitive health and claims data from health care providers participating in the federal 340B program, which requires pharmaceutical manufacturers to offer discounted drugs to eligible hospitals and clinics. Without action, Kansas healthcare providers face continued pressure from private intermediaries demanding proprietary information beyond what federal or state law requires, potentially undermining the program’s ability to generate supplemental revenue for indigent and uninsured patient care.
What Happened
House Speaker Dan Hawkins, a Wichita Republican, has used his authority as presiding officer to prevent the Kansas House from voting on SB 284 since the Senate approved it in March 2025. Rather than allow the bill to move forward, Hawkins, who chairs the House Interstate Cooperation Committee, has transferred the legislation seven times between his committee and the House Health and Human Services Committee without either body advancing it.
The Senate bill specifically prohibits private companies from demanding excessive health information, claims data, and purchasing documents from 340B program participants beyond what state or federal law requires. The legislation would authorize the state to investigate complaints and impose civil penalties against violators. Hawkins’ blocking tactics have frustrated both Republican and Democratic House members who support the measure.
In response to the continued stalling, a coalition of approximately 50 House Republicans and dozens of House Democrats prepared to invoke a discharge procedure last week—a parliamentary mechanism that would allow them to bring SB 284 directly to the House floor without the speaker’s approval. The effort reflected rare bipartisan frustration with Hawkins’ obstruction.
Hawkins’ position is notable given his background: the speaker has worked in the insurance industry for 30 years and is now a candidate for Kansas insurance commissioner, a statewide elected position. His candidacy makes him a lame-duck leader, yet he retains full authority over which bills advance through the House.
By the Numbers
- The Senate passed SB 284 with overwhelming bipartisan support in March 2025
- The House speaker transferred the bill seven times between committees since January 2026
- Approximately 50 House Republicans and dozens of House Democrats support advancing the bill
- Hawkins has 30 years of experience in the insurance industry
- The bill has remained stalled for over 12 months without committee action or House floor debate
Zoom Out
Prescription drug pricing remains a contentious issue across states and at the federal level. The 340B program, established by Congress in 1992, has become increasingly important as healthcare costs rise. The program allows eligible hospitals and clinics—including safety-net providers serving uninsured and low-income patients—to purchase drugs at substantial discounts from manufacturers, enabling these institutions to reinvest savings into patient services.
However, private intermediaries and pharmacy benefit managers have increasingly demanded access to detailed purchasing and claims data from 340B participants, ostensibly to verify compliance. These demands often exceed statutory requirements and can compromise providers’ competitive positions and proprietary information. Several states have explored legislation to protect 340B participants from excessive data demands.
Kansas’ approach through SB 284 mirrors efforts in other states to safeguard the 340B program’s integrity. The bill’s focus on preventing overreach by private companies reflects a broader national concern about the role of intermediaries in drug distribution and pricing systems.
What’s Next
The discharge petition filed by House members will determine whether SB 284 reaches the House floor without Speaker Hawkins’ consent. If the petition succeeds, the full House would vote on advancing the bill to debate and final passage. The timeline for such a vote depends on legislative procedures and whether leadership attempts to delay or obstruct the process further.
Alternatively, if the discharge effort fails, SB 284 could remain bottled up in committee through the legislative session, effectively killing the bill until the next session begins. The outcome will signal whether the House Republican and Democratic coalition can overcome leadership obstruction on healthcare policy.